ACUTE LYMPHOBLASTIC LEUKEMIA THERAPEUTICS MARKET ANALYSIS

Acute Lymphoblastic Leukemia Therapeutics Market, by Drug Type, (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Therapy Drugs, and Others), by Indication (Precursor B Cell ALL, Mature B Cell ALL, and Precursor T Cell ALL), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Nov 2024
Code : CMI1606
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

However, higher treatment cost and adverse effects of the CAR-T cell therapy are factors restraining the market growth. According to the survey by American Journal of Managed Care (AJMC), February 2018, the initial treatment cost of for the approved CAR-T cell therapies developed by Novartis AG is around US$ 475,000 per patient, respectively.

Restaints